Intra-Cellular Therapies ... (ITCI)
NASDAQ: ITCI
· Real-Time Price · USD
131.87
0.00 (0.00%)
At close: Apr 01, 2025, 3:59 PM
0.00% (1D)
| Bid | 131.83 |
| Market Cap | 14.05B |
| Revenue (ttm) | 680.64M |
| Net Income (ttm) | -74.68M |
| EPS (ttm) | -0.73 |
| PE Ratio (ttm) | -180.64 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 131.92 |
| Volume | 16,042,154 |
| Avg. Volume (20D) | 3,621,742 |
| Open | 131.87 |
| Previous Close | 131.87 |
| Day's Range | 131.87 - 131.87 |
| 52-Week Range | 64.09 - 131.98 |
| Beta | 0.46 |
About ITCI
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ITCI
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ITCI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Intra-Cellular Therapies Inc. is scheduled to release its earnings on May 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
Intra-Cellular Therapies shares are trading higher...
Unlock content with
Pro Subscription
6 months ago
Intra-Cellular Therapies shares are trading higher after the company reported better-than-expected Q3 revenue results and raised its FY24 net product sales guidance. Also, Needham reiterated a Buy rating on the stock.
